Botensilimab And Balstilimab – ASCO GI 2025 And Beyond Shohei Ohtani [SwNgWKUgrjp]
Tag: #Shohei Ohtani, #roma meteo, #aumento di capitale, #fisher college
At the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal jon jones Cancers Symposium (GI) in San Francisco, Agenus presented new data on its next-generation immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for colorectal cancer. Join Agenus Chief Medical Officer Dr. Steven O'Day as he explores these findings.
Learn more at: devin vassell www.agenusbio.com
Botensilimab and balstilimab the rock are investigational agents and have not been approved for use in any jurisdiction worldwide.